Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
ConclusionsThese data provide a rationale for further exploring the efficacy of nivolumab and other checkpoint inhibitors in soft tissue and bone sarcoma.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research
More News: Bone Cancers | Cancer & Oncology | Chondrosarcoma | Leiomyosarcoma | Osteosarcoma | Sarcomas | Toxicology